BioCryst Pharmaceuticals BCRX Royalty financing obligations
Royalty financing obligations at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:RoyaltyFinancingLiabilitiesCurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's royalty financing obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's royalty financing obligations?
- BioCryst Pharmaceuticals (BCRX) reported royalty financing obligations of $40.32M in Q1 2026.
- How has BioCryst Pharmaceuticals's royalty financing obligations changed year-over-year?
- BioCryst Pharmaceuticals's royalty financing obligations increased by 17.5% year-over-year, from $34.31M to $40.32M.
- What is the long-term trend for BioCryst Pharmaceuticals's royalty financing obligations?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's royalty financing obligations has grown at a 27.7% compound annual growth rate (CAGR), from $23.57M to $38.46M.
- What does royalty financing obligations mean?
- This represents the portion of royalty-based financing arrangements due within the next twelve months, where the company has received upfront capital in exchange for future royalty payments on product sales. It serves as a measure of near-term debt service obligations tied directly to commercial revenue streams. Investors use this to evaluate the company's short-term leverage and the impact of non-dilutive financing on future cash flows.